News in Brief
Pharmacology - Jan 21
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
wire - news in brief
Category
Results 51 - 100 of 392.
"100 women and 1000 more": Jeanne Mengis
Seminario IdEP "Raising the Full Retirement Age: Defaults vs Incentives", Stefan Staubli Faculty of Economics Functional Synthesis with Examples Faculty of Informatics Visiting Alumni: Valeria Croce,
Seminario IdEP "Raising the Full Retirement Age: Defaults vs Incentives", Stefan Staubli Faculty of Economics Functional Synthesis with Examples Faculty of Informatics Visiting Alumni: Valeria Croce,
The Swiss National Science Foundation will support a new NCCR, "Evolving language", led by the Universities of Geneva and Zurich.
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra
Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.
Novartis receives positive CHMP opinion for Beovu (brolucizumab) for the treatment of wet AMD
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).
Daylight plays an essential role in sleep, alertness and hormone regulation.
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Climate change not only has an impact on the environment, but also significant effects on global health.
Roche receives CE Mark for its Accu-Chek SugarView app
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
ClearSpace, a spin-off of EPFL's Space Center (eSpace), has been selected to lead a major European Space Agency (ESA) space debris de-orbiting project with a total budget topping ¤100 million.
Using virtual reality to overcome unconscious biases
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
"100 women and 1000 more": Silvia Santini
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
ETH Zurich is planning to step up its research activities in Singapore. It aims to extend its current Future Resilient Systems programme by five years and to launch a new programme, Future Health Technologies, in the coming year. On Thursday, 5 December, ETH Zurich announced its future endeavours involving Singapore.
The space telescope CHEOPS is scheduled to begin its journey into space on Tuesday, December 17th on board a Soyuz rocket from the European Space Agency (ESA) in Kourou, French Guiana.
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Digital’s doppelganger: The myth of analog media - Towards the "Rethinking Digital Myths" conference
Visiting Alumni: Ktimene Axetell, VP Insights, Arrivalist Visiting Alumni: Valeria Croce, Manager International Relations and Insights, Eurail BV Fall Semester Projects Presentations 2019 Faculty of
Visiting Alumni: Ktimene Axetell, VP Insights, Arrivalist Visiting Alumni: Valeria Croce, Manager International Relations and Insights, Eurail BV Fall Semester Projects Presentations 2019 Faculty of
The space telescope CHEOPS is scheduled to begin its journey into space on Tuesday, December 17th on board a Soyuz rocket from the European Space Agency (ESA) in Kourou, French Guiana.
Switzerland’s influence on European energy policy continues to decline
What would be the consequences of failed negotiations over an electricity agreement between Switzerland and the EU?
What would be the consequences of failed negotiations over an electricity agreement between Switzerland and the EU?
Computer scientist David Dao develops intelligent algorithms that use satellite and drone images of rainforests to predict where the next sites of deforestation will be.
Animal development is a unidirectional process that steers undifferentiated cells of the early embryo into specialized cell types such as brain, muscle or skin cells. Once differentiated, there is almost no way back. A notable exception is the de-differentiation of mature into immature cell types during injured tissue regeneration.
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Climate change not only affects the environment, but also has significant consequences on global health.
Proteomics pioneer Ruedi Aebersold is retiring soon. Protein analysis was his life's work, and he paved the way for countless protein researchers around the world.
News in Brief
Pharmacology - Jan 21
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma